Advances in the detection of biomarkers for ischemic stroke.

Front Neurol

Center for Clinical Laboratory, General Hospital of the Yangtze River Shipping, Wuhan Brain Hospital, Wuhan, Hubei, China.

Published: February 2025

Ischemic stroke is a leading cause of mortality and morbidity globally. Prompt intervention is essential for arresting disease progression and minimizing central nervous system damage. Although imaging studies play a significant role in diagnosing ischemic stroke, their high costs and limited sensitivity often result in diagnostic and treatment delays. Blood biomarkers have shown considerable promise in the diagnosis and prognosis of ischemic stroke. Serum markers, closely associated with stroke pathophysiology, aid in diagnosis, subtype identification, prediction of disease progression, early neurological deterioration, and recurrence. Their advantages are particularly pronounced due to their low cost and rapid results. Despite the identification of numerous candidate blood biomarkers, their clinical application requires rigorous research and thorough validation. This review focuses on various blood biomarkers related to ischemic stroke, including coagulation and fibrinolysis-related factors, endothelial dysfunction markers, inflammatory biomarkers, neuronal and axonal injury markers, exosomes with their circular RNAs and other relevant molecules. It also summarizes the latest methods and techniques for stroke biomarker detection, aiming to provide critical references for the clinical application of key stroke biomarkers.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11891058PMC
http://dx.doi.org/10.3389/fneur.2025.1488726DOI Listing

Publication Analysis

Top Keywords

ischemic stroke
20
blood biomarkers
12
biomarkers ischemic
8
stroke
8
disease progression
8
clinical application
8
biomarkers
6
ischemic
5
advances detection
4
detection biomarkers
4

Similar Publications

Advances in the detection of biomarkers for ischemic stroke.

Front Neurol

February 2025

Center for Clinical Laboratory, General Hospital of the Yangtze River Shipping, Wuhan Brain Hospital, Wuhan, Hubei, China.

Ischemic stroke is a leading cause of mortality and morbidity globally. Prompt intervention is essential for arresting disease progression and minimizing central nervous system damage. Although imaging studies play a significant role in diagnosing ischemic stroke, their high costs and limited sensitivity often result in diagnostic and treatment delays.

View Article and Find Full Text PDF

Objectives: COVID-19 is an independent risk factor for ischemic stroke. Studies from early in the pandemic show increased rates of unfavorable recanalization, poor outcomes, and mortality in patients who were COVID-19 positive at the time of mechanical thrombectomy. However, there are currently no studies examining these parameters during the later pandemic when circulating variants were less virulent.

View Article and Find Full Text PDF

Background Hypertension is a risk factor for developing stroke after transient ischemic attack (TIA), yet it is unknown if stroke risk is altered by emergency department (ED) antihypertensive therapy. We aimed to investigate stroke rate in a population of TIA patients presenting with elevated blood pressure in the ED, comparing those who received antihypertensive medication in the ED to those who received no treatment. Secondarily, we aimed to assess the association between ED antihypertensive therapy and intensive care unit (ICU) admit rates, hospital length of stay (LOS), and discharge disposition setting in this population.

View Article and Find Full Text PDF

Intravenous thrombolysis (IVT) with recombinant tissue plasminogen activator (rt-PA) is the preferred treatment for acute ischemic stroke (AIS). Nevertheless, only approximately half of patients undergoing IVT experience positive outcomes. The objective of the study was to examine the clinical characteristics of patients with AIS and identify predictors for unfavorable clinical outcomes at 3 months after IVT.

View Article and Find Full Text PDF

Background: Although existing studies have reported associations between blood group A and cardiometabolic diseases (CMD), most have focused on dominant inheritance models. However, genome-wide association studies have mostly been based on additive genotypes. This study aims to investigate the association between the blood group A allele and 15 CMD using recessive, dominant, and additive models and identify potential mediators.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!